chevron_leftBack
As of 24 April 2025, Mainz Biomed N.V. has a market cap of $9.57M USD, ranking #33276 globally and #386 in Germany. It ranks #3315 in the Healthcare sector, and #172 in the Diagnostics & Research industry.
Key Stats
Market Cap
$9.57MUSD
Enterprise Value
$6.61MUSD
Revenue (TTM)
$893.99KUSD
EBITDA (TTM)
-$17.71MUSD
Net Income (TTM)
-$21.65MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Guido Baechler
open_in_new
Employees
26
Founded
2021
IPO
05 Nov 2021
Website
mainzbiomed.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.3% | -2.2% | -32% | -30% | -74% | -91% |
Upcoming Earnings
Earnings Date
Tue, May 6
Earnings Time
sunny
Before Open
EPS Estimate
-$2.80
Revenue Estimate
$300.0K
40% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
MYNZ
Mainz Biomed NV
ISIN: NL0015000LC2
Shares Out.:
Shares Outstanding:
3.039M1
Shares Float:
2.888M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.15 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Mainz Biomed N.V.
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
Country |
|---|---|---|
NanoRepro AG
XETRA: NN6
|
$19.38M
102%
17.03M EUR
|
|
Centogene N.V.
OTCMKTS: CNTGF
|
$4.36M
-54%
|
